孟鲁司特对慢性肺心病肺动脉高压的治疗效应研究

为探讨半胱氨酸白三烯（CysLT）在慢性肺心病肺动脉高压发病中的作用和评价其受体拮抗剂孟鲁司特对慢性肺心病肺动脉高压的治疗效应。以白三烯受体拮抗剂孟鲁司特对慢性肺心病并肺动脉高压的患者进行治疗．40例患者分为2组：对照组和孟鲁司特治疗组，观察两组治疗前后肺动脉压力，右室肥厚和动脉血氧分压的变化以及血浆中LTC4浓度的变化。超声心动图检测肺动脉压及右心室内径、采用酶免疫法检测血浆中LTC4浓度、血气分析测定PaO2等指标。孟鲁司特治疗组治疗后与治疗前比较PaO2升高、肺动脉压降低；孟鲁司特治疗组治疗后与对照组比较PaO2升高、肺动脉压降低更多（P均〈0．01），而血浆中LTC4浓度与对照组比较无显著性差异（P〉0．05）。因此．白三烯受体拮抗剂孟鲁司特能扩张血管、降低肺动脉压，并使动脉血氧分压上升，对慢性肺心病具有一定治疗作用。

The Effect of Montelukast in the Therapy of Pulmonary Hypertension in Chronic Pulmonary Heart Disease Patients

Objective: To discuss the role of CysLT in the cause of chronic pulmonary heart disease and to evaluate the effect of montelukast,leukotrient antagonist in the therapy of pulmonary hypertension in chronic pulmonary heart disease.Methods:We give the therapy of Montelukast leukotrient antagonist to the patients of chronic pulmonary heart disease,those 40 patients were randomly divided into two groups:therapy and control.To study the change of the pressure of pulmonary artery,right ventricular with thick wall,arterial blood oxygen pressure,LTC_4 level in serum before and after the therapy.To get the pressure of pulmonary artery and right ventricle with thicking wall by Echocardiography;arterial blood oxygen pressure by blood gas analysis;LTC_4 level in serum by ELASA.Results:After the therapy the pressure of pulmonary artery is decreased and arterial blood oxygen pressure increased,and more than the control group.But the LTC_4 level in serum is no difference with the control group.Conclusion:montelukast,leukotrient antagonist has effect in the therapy of pulmonary hypertension in chronic pulmonary heart disease patients by dilating the artery,and decrease the pressure of pulmonary artery and increasing arterial blood oxygen pressure.